A new vaccine designed to prime the immune system to recognise and fight lung cancer has been tested on UK patients for the first time.

Researchers leading the trial have said that BioNTech’s BNT116 vaccine could improve survival rates among people with the disease, and hope that it could eventually become the standard of care worldwide.

It works by presenting the immune system with tumour markers from non-small cell lung cancer, the most common form of the disease, to prime the body to fight cancer cells expressing these markers.